Key Drivers
- Strong Cash Flow
- Rising Leverage
- Quarterly Losses
AIAI Summary
MRK is now a portfolio-replacement investment: its attractive valuation and 3% dividend depend on multiple pipeline launches scaling fast enough to offset Keytruda's 2028 patent cliff, while the recent margin collapse and rising leverage make execution evidence—not near-term Keytruda growth—the key catalyst to watch.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Leverage
- •Quarterly Losses
MRK's strong annual cash generation and margins support its dividend, but worsening quarterly profitability, rising leverage, and weaker liquidity heighten valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trading
- •Lower highs
- •Neutral momentum
MRK is range-bound with neutral momentum; watch $143.00 support for downside risk and $151.45–$155.53 for a bullish breakout.
Price peaked at $155.53 before forming lower highs
Sentiment & News
Key News Insights:
- •Keytruda Momentum
- •Pipeline Expansion
- •Patent Expiry
Merck's strong Keytruda-led momentum and advancing pipeline support near-term upside, but 2028 patent-expiry replacement growth remains the key investor risk.
Positive clinical and commercial progress may support shares, though execution on post-Keytruda growth drivers will be critical
Similar Companies in Healthcare
Other companies in the same sector with AI ratings